Modified vasoactive intestinal peptides
OwnerHomayoun SADEGHI, Suzanne DAGHER +1inventors
InventorsHomayoun SADEGHI, Suzanne DAGHER, Andrew TURNER
Life of this patent
Estimating the term…
Abstract
The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.
Claims18
A method of treating hypertension, comprising administering to a subject a pharmaceutical composition comprising a Vasoactive Intestinal Peptide Receptor (VPAC) agonist comprising the amino acid sequence of SEQ ID NO:13 having an N-terminal methionine, and an elastin-like polypeptide (ELP) at the C-terminus, and one or more pharmaceutically acceptable excipients, wherein the ELP comprises at least 90 repeat units of VPGXG (SEQ ID NO:
- 3), where X is independently selected from Val, Ala, and Gly.
A method of treating hypertension, comprising administering to a subject a pharmaceutical composition comprising a Vasoactive Intestinal Peptide Receptor (VPAC) agonist comprising the amino acid sequence of SEQ ID NO:13 having an N-terminal methionine, and an elastin-like polypeptide (ELP) at the C-terminus, and one or more pharmaceutically acceptable excipients, wherein the ELP comprises at least 90 units of VPGXG (SEQ ID NO:3), where X is Val, Ala, and Gly at a ratio of 5:2:3.
Dependencies are inferred from the claim text.